Terminal
Infiniti Feed

Retatrutide approval odds fall to 5.6% in Polymarket trading

No significant new prediction-platform headline in the last 30 minutes; news search recirculated only items already used, held out or web-held today (the midterm…

Polymarket’s contract on whether the FDA will approve Retatrutide this year was priced at 5.6%, down 3.7 percentage points, in the supplied market snapshot published Nov 1, 2026, at 8:54 AM ET.

The contract had recorded $598K in trading volume. The price reflects market expectations for approval within the year, rather than a determination of the drug’s regulatory status.

No fresh catalyst identified

The accompanying summary identified no significant new prediction-platform headline in the preceding 30 minutes. It said a news search had resurfaced only material already used or held back that day.

No source links or further regulatory reporting were provided. The available material therefore does not establish what drove the price decline or connect it to a new FDA development.

What it means for prediction markets

  • Lower approval pricing: The 3.7-percentage-point decline left the year-end approval contract at 5.6%.
  • Volume is not an explanation: The $598K traded provides activity context but does not identify the cause of the move.
  • Timing matters: This contract concerns approval this year; its price should not be read as an estimate of eventual approval.
PredictionMarketsPolymarketSenateCongressInfiniti MarketsInfiniti Signals

Sources & attribution

Published
  1. Source
    Polymarketpolymarket.com
    Publisher
    https://polymarket.com
    Source URL
    The feed did not publish this story's article address.

Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Polymarket”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.

Related